Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of rituximab + polatuzumab vedotin + glofitamab in older untreated aggressive B-cell lymphoma patients ineligible for full-dose R-CHOP
2022-003398-51Phase 2Active
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab, polatuzumab vedotin and glofitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Institut für Klinische Krebsforschung. Primary endpoint: 1-year progression-free survival rate. Started Jan 2023; status: active.
02
Drugs
rituximabpolatuzumab vedotinglofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2022-003398-51.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-003398-51.